An oral patch for controlling drug release on demand and its preparation method and application

By using a combination of multi-layer nanostructures and photothermal initiators in oral patches, the effects of drug release on demand and oral epithelial regeneration are achieved, and the problem of low drug release control and treatment efficiency in the prior art is solved. It is suitable for Treatment of various oral diseases.

CN115245504BActive Publication Date: 2024-11-26QINGDAO UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210036693.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-13
Publication Date
2024-11-26
Estimated Expiration
2042-01-13

AI Technical Summary

Technical Problem

The prior art cannot effectively control the on-demand release of drugs in oral patches, and cannot promote oral epithelial regeneration, resulting in inefficiency in treatment.

Method used

Using a multi-layer nanoplate structure, the inner layer is a medically degradable polymer nanofiber membrane with a uniaxial random or centripetal orientation. The drug-loading particles are composed of a core layer and a shell layer. The core layer contains drugs or biologically active molecules and Photothermal initiator, the shell contains phase change material, which realizes drug release on demand through near-infrared light stimulation, and adds bioactive substances such as decellularized dermal matrix to the inner layer to promote epithelial regeneration.

Benefits of technology

It realizes the control of drug release on demand and regeneration of oral epithelium, improves treatment efficiency, is suitable for the treatment of different oral diseases, has a flexible structural design, a wide range of applications, and is suitable for large-scale promotion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115245504B_ABST
    Figure CN115245504B_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of oral patches, and relates to an oral patch for controlling the on-demand release of drugs, and a preparation method and application thereof. The main structure of the patch comprises an inner layer, drug-carrying particles and an outer layer, wherein the inner layer of the patch is a uniaxial random or centripetally oriented medical degradable polymer nanofiber membrane; the drug-carrying particles are located between the inner layer and the outer layer of the patch, and are deposited on the inner layer of the patch; the outer layer of the patch is a medical degradable polymer random nanofiber; adding bioactive substances to the inner layer of the patch can promote oral epithelial regeneration, and different drugs can be loaded and different bioactive substances can be added to the inner layer for different oral diseases; in an in vitro controlled release drug administration method, infrared irradiation is only required to stimulate drug release when needed, thereby eliminating the trouble of frequent dressing changes; the structural design of the invention is flexible and ingenious, the application range is wide, the preparation method is simple, it is suitable for large-scale promotion, and the market prospect is broad.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention belongs to the technical field of oral patches, and relates to an oral patch for controlling the on-demand release of drugs, and a preparation method and application thereof. The drug-loaded particles in the middle layer of the oral patch can control the in-situ on-demand release of drugs through infrared control, and are used for the treatment of oral diseases. Background technology:

[0002] Oral health is essential to our daily lives. According to the World Health Organization, oral diseases have become an important issue affecting human health due to their high incidence and prevalence. Oral problems affect many physiological functions of the human body, including sensory functions, speaking, chewing and eating. Therefore, once oral tissues are defective, damaged or diseased, it will seriously affect people's quality of life and even threaten personal life safety. At present, oral diseases are mainly divided into the following categories: maxillofacial defects, periodontal disease (gingival inflammation, periodontal ligament, alveolar bone, cementum loss), pulp disease and dental hard tissue defects. To date, there are still huge challenges in basic research and clinical treatment in the field of oral health. For example, periodontal disease is considered to be the primary cause of damage to teeth and their surrounding bones and soft tissues. However, current treatment strategies still cannot completely eliminate the pathogens that cause periodontal disease. In addition, current treatments for oral cancer, such as surgery, radiotherapy, chemotherapy or synergistic therapy, have limited ability to prevent or delay the recurrence of oral cancer. Therefore, seeking effective treatments for oral diseases is the key to solving the above problems.

[0003] The rapid development of biomedical materials highlights their great value and potential in the treatment of oral diseases. To date, many implantable and degradable biomaterials have shown great capabilities in the prevention, treatment and adjuvant treatment of oral diseases due to their strong targeting and specificity. For example, implantable hydrogels, microspheres, drug-loaded microsphere hydrogels / aerogels and drug-loaded electrospun nanofibers with good biocompatibility have been used to treat oral diseases such as periodontal disease, mucositis and oral cancer. Among them, as a type of scaffold in tissue engineering, electrospun nanofibers have shown great potential in biomedical fields such as oral disease treatment. Electrospinning is a versatile manufacturing process that can produce fiber scaffolds with a variety of structures and biological functions. Simply put, the polymer solution is sprayed and rotated under a strong electric field, and then the droplet at the needle tip changes from a sphere to a cone (Taylor cone) and extends from the needle tip to form a filament, thereby producing nanoscale polymer filaments. Electrospinning can be used to prepare materials with adjustable pore size (tens of nanometers to several micrometers), high porosity, good biocompatibility and high mechanical strength. More importantly, it has great flexibility and can combine polymers with other components such as bioactive molecules, nanoparticles and growth factors, etc. This combination can endow the scaffold with specially designed structure and biological functions, making electrospun nanofibers an important biomaterial for the treatment of oral diseases.

[0004] In addition, drug-loaded microspheres made by electrostatic spraying or coaxial electrostatic spraying can be combined with hydrogels or electrospun nanofibers to achieve the effect of in situ drug release, further improving the efficiency of drug treatment. At the same time, in order to improve the targeting specificity of drugs and avoid premature drug release, various gating of specific microenvironment responses are used in smart drug delivery platforms, including acid-base environment, specific biomarkers, biomolecules, temperature, electrostatic interactions, etc. When exposed to certain stimulation conditions, environmentally responsive biomaterials will change their conformation and release drugs to the damaged area. However, this design still does not achieve the effect of controlled release. Therefore, in order to improve the efficiency of treatment, it is necessary to develop an intelligent drug delivery system to achieve on-demand release of drugs in space.

[0005] In recent studies, in vitro controlled drug release methods (such as ultrasound, light, temperature, etc.) have been developed and used for on-demand drug release. As a new excitation method, near-infrared light (NIR) stimulation has attracted widespread attention due to its strong penetration ability, high spatiotemporal resolution, and non-toxicity to cells and various tissues. Therefore, combining NIR stimulation with biomaterials containing photothermal effect initiators is an ideal system for achieving on-demand drug release. There are currently no reports on oral patches that can release drugs on demand and promote oral epithelial regeneration. Summary of the invention:

[0006] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a method for preparing a multilayer nanopatch that controls drug release on demand and promotes oral epithelial regeneration; the oral patch can load corresponding drugs according to specific oral diseases and treat related diseases by controlling the release of drugs through infrared. At the same time, adding bioactive substances to the inner layer of fibers can promote epithelial regeneration.

[0007] In order to achieve the above-mentioned purpose, the present invention provides an oral patch for controlling the on-demand release of drugs, the main structure of which includes an inner layer of the patch, drug-loaded particles and an outer layer of the patch, the inner layer of the patch is a uniaxial random or centripetally oriented medical degradable polymer nanofiber membrane; the drug-loaded particles are located between the inner layer of the patch and the outer layer of the patch, and are deposited on the inner layer of the patch; the outer layer of the patch is medical degradable polymer random nanofibers, which serve as an outer layer covering the deposited drug-loaded particles.

[0008] The inner layer of the patch contains biologically active substances.

[0009] The bioactive substance is acellular dermal matrix.

[0010] The medical degradable polymer is at least one of polylactic acid, polycaprolactone, polylactic acid-glycolic acid copolymer and polylactic acid-caprolactone copolymer.

[0011] The drug-loaded particles include a core layer and a shell layer, wherein the core layer is a mixture of drugs or bioactive molecules and photothermal initiators, and the shell layer is a mixture containing phase change materials.

[0012] The drug or bioactive molecule is at least one of low molecular weight brown algae polysaccharide, naringin, dexamethasone acetate, and metronidazole; the photothermal initiator is at least one of indocyanine green and heptamethine cyanine small molecule dyes.

[0013] The phase change material is lauric acid and stearic acid, and the mass ratio of the two is at least one of 4:1, 3:1, 2:1, and 1:1.

[0014] The present invention also provides a method for preparing the oral patch for controlling the on-demand release of drugs, the specific steps comprising:

[0015] (1) Preparing the inner layer of the patch: blending the medical degradable polymer and the bioactive substance in an organic solvent and dissolving them uniformly to obtain a spinning solution, and then using a single-nozzle electrospinning device to prepare a uniaxial random or centripetally oriented polymer nanofiber membrane, which is the inner layer of the patch;

[0016] (2) Depositing drug-loaded particles: The drug-loaded particles are prepared by spraying the shell layer solution and the core layer solution through a coaxial electrostatic spray device, and the sprayed drug-loaded particles are deposited on the inner layer surface of the patch obtained in step (1);

[0017] (3) Preparing the outer layer of the patch: dissolving the medical degradable polymer in an organic solvent, and then using existing electrospinning equipment to prepare a random nanofiber membrane, which is then covered on the inner layer surface of the patch where the drug-loaded particles are deposited, thereby obtaining a three-layer structured oral patch that controls the on-demand release of drugs.

[0018] The shell layer solution is a mixed solution containing a phase change material, and the core layer solution is a mixed solution containing drugs or bioactive molecules and a photothermal initiator.

[0019] In the step (1), the mass ratio of the medical degradable polymer to the bioactive substance is 1:(0.5-1); and the volume ratio of the total mass of the medical degradable polymer and the bioactive substance to the organic solvent is (0.5-2) g:10 mL.

[0020] The electrospinning equipment in step (1) comprises a propulsion device, a syringe, a high-voltage electrostatic generator and a receiving plate.

[0021] The parameters of the electrospinning equipment in step (1) are as follows: the flow rate of the medical degradable polymer and bioactive substance blended spinning solution is 1-5 mL / h, the nozzle voltage is 10-20 kV, and the distance between the nozzle and the receiving plate is 12-15 cm.

[0022] The organic solvent in step (1) or step (3) is one of hexafluoroisopropanol, dichloromethane, trifluoroethanol, trifluoroacetic acid, anhydrous ethanol, acetic acid and a dichloromethane / N,N-dimethylformamide mixed solvent.

[0023] The shell layer solution of the drug-loaded particles in step (2) is a dichloromethane / anhydrous ethanol solution of lauric acid and stearic acid, and the drugs or bioactive molecular drugs in the core layer solution are low molecular weight fucoidan, naringin, dexamethasone acetate, and metronidazole; the concentration of the photothermal initiator in the core layer solution is adjusted according to the heat converted by the photothermal initiator under appropriate irradiation intensity and time to dissolve the shell layer; the solvent is deionized water, phosphate buffer, or an aqueous solution of gelatin.

[0024] The preparation parameters of the drug-loaded microparticles in step (2) are: the flow rate of the shell solution is 1-5 mL / h, the flow rate of the core solution is 0.1-1.0 mL / h, the nozzle voltage is 15-20 kV, the receiving plate is grounded, and the distance between the nozzle and the plate is 12-15 cm.

[0025] In the step (3), the volume ratio of the mass of the medical degradable polymer to the organic solvent is (0.5-1) g:10 mL.

[0026] The parameters of the electrospinning equipment in step (3) are as follows: the flow rate of the spinning solution of the medical degradable polymer is 1-5 mL / h, the nozzle voltage is 10-20 kV, and the distance between the nozzle and the receiving plate is 12-15 cm.

[0027] The present invention also provides application of the oral patch for controlling the on-demand release of drugs in preparing a patch for treating oral diseases.

[0028] In general, the inner nanofiber membrane of the oral patch is in direct contact with the damaged area and is made of a mixture of medical degradable polymers and bioactive substances through an electrospinning device. The addition of bioactive substances effectively promotes the proliferation of oral epithelial cells and promotes the regeneration of oral epithelium in the damaged area. The drug-loaded particles are encapsulated with drugs and photothermal initiators inside the particles through coaxial electrostatic spray technology and deposited on the inner nanofiber membrane. The photothermal initiator is a thermosensitive PCMs composed of a certain proportion of lauric acid and stearic acid, with a melting point of 39°C, slightly higher than the physiological temperature of the human body, and will not damage any cells and tissues. When NIR irradiates the oral patch, the irradiated photothermal initiator absorbs light and converts it into heat, thereby melting the outer shell of the PCM and realizing the on-demand release of the drug. The outer layer of the oral patch is random nanofibers prepared by electrospinning, which serve as the substrate layer. The hydrophobicity and mechanical strength of this layer enable it to prevent the patch from falling off due to chewing, drinking water or saliva flow. Therefore, the oral patch achieves the effect of in vitro controlled drug release on demand and also has the function of promoting oral epithelial regeneration.

[0029] Compared with the prior art, the present invention has the following beneficial effects: (1) Compared with the existing oral patch, the present invention is an in vitro controlled release drug delivery method, which only needs to use infrared irradiation to stimulate drug release when needed, eliminating the trouble of frequent dressing changes; (2) The random or centripetal oriented nanofibers in the inner layer of the patch can promote oral epithelial regeneration due to the addition of bioactive substances, so the present invention can achieve the purpose of promoting epithelial regeneration while treating diseases; (3) The present invention can select different loading drugs and add different bioactive substances to the inner layer for different oral diseases. The structural design of the present invention is flexible and ingenious, with a wide range of applications, a simple preparation method, suitable for large-scale promotion, and broad market prospects. Description of the drawings:

[0030] Figure 1 These are the physical pictures and cross-sectional electron microscope pictures of the oral patch involved in the present invention, wherein A is the cross-sectional electron microscope picture, and B, C and D are the physical pictures of the side, front and back sides respectively.

[0031] Figure 2 These are optical images of the microparticles loaded with bioactive substances or drug molecules and photothermal initiators involved in the present invention and scanning electron microscope (SEM) images of each layer of the patch, wherein A is an optical microscope rhodamine B fluorescence image, B is a SEM image of the microparticle morphology, C is a SEM image of the nanofibers in the inner layer of the patch, and D is a SEM image of the nanofibers in the outer layer of the patch.

[0032] Figure 3 This is the drug release curve of the drug-loaded microparticles of the present invention after each round of infrared irradiation, wherein "-" represents no infrared irradiation; "+" represents infrared irradiation.

[0033] Figure 4 This is a schematic diagram of the experimental results of the effect of the oral patch of Example 4 of the present invention on the proliferation of oral epithelial cells, wherein "-" represents no infrared irradiation; "+" represents infrared irradiation.

[0034] Figure 5 This is a schematic diagram of the experimental results of the effect of the oral patch of Example 5 of the present invention on the morphology of oral epithelial cells, wherein red represents actin and blue represents cell nuclei; "-" represents no infrared irradiation; and "+" represents infrared irradiation.

[0035] Figure 6 This is a schematic diagram of the experimental results of the effect of the oral patch of Example 6 of the present invention on the morphology of oral squamous cell carcinoma cells, green represents actin, blue represents cell nuclei; "-" represents no infrared irradiation; "+" represents infrared irradiation.

[0036] Figure 7 This is a schematic diagram of the experimental results of the effect of the oral patch of Example 7 of the present invention on the apoptosis of oral squamous cell carcinoma cells, wherein "-" represents no infrared irradiation; "+" represents infrared irradiation. Specific implementation method:

[0037] The present invention will be further described below through specific embodiments in conjunction with the accompanying drawings.

[0038] Embodiment 1:

[0039] This embodiment relates to a method for preparing an oral patch for controlled on-demand drug release. The raw materials for preparing polymer electrospun nanofibers are polycaprolactone (PCL) and acellular dermal matrix (ADM), and the active drug molecule loaded by the microparticles is low molecular weight brown algae polysaccharide (LMWF). The specific steps include:

[0040] (1) Preparation of the inner layer of the patch: accurately weigh 0.05 g of PCL and 0.05 g of ADM with an electronic balance and dissolve them in 1 mL of hexafluoroisopropanol, stir them with a magnetic stirrer overnight, and stir them evenly to obtain a PCL / ADM spinning solution with a total mass concentration of 0.1 g / mL; use an existing electrospinning device to prepare a PCL / ADM random nanofiber membrane, and the spinning parameters are: the spinning solution flow rate is 1 mL / h, the distance between the nozzle and the receiving plate is 15 cm, the nozzle voltage is 15 kV, and the receiving plate voltage is -3 kV. After 1 hour, a PCL / ADM random nanofiber membrane is obtained;

[0041] (2) Deposition of drug-loaded particles: The PCL / ADM random nanofiber membrane obtained in step (1) is fixed on a receiving plate, the receiving plate is connected to negative pressure, the distance between the receiving plate and the nozzle of the coaxial electrostatic spray device is 15 cm, the coaxial electrostatic spray device sprays the drug-loaded particles to the surface of the nanofiber membrane, and the carrier particles are deposited on the surface of the nanofiber membrane for 10 minutes; the carrier particles are prepared by coaxial electrostatic spraying of a shell solution and a core solution, wherein the shell solution is a dichloromethane / anhydrous ethanol solution containing lauric acid (LA) and stearic acid (SA), and the core solution is a gelatin aqueous solution containing LMWF and indocyanine green (ICG); the parameters of the coaxial electrostatic spray device are set as follows: the flow rate of the shell solution is 3 mL / h, the flow rate of the core solution is 1 mL / h, and the nozzle voltage is 15 kV;

[0042] The shell solution preparation method is as follows: accurately weigh 0.8 g of LA and 0.2 g of SA using an electronic balance and dissolve them in 5 mL of a dichloromethane / anhydrous ethanol mixed solvent, wherein the volume ratio of dichloromethane to anhydrous ethanol in the mixed solvent is 4:1, and stir with a magnetic stirrer for 5 hours until the mixture is uniformly stirred to obtain a dichloromethane / anhydrous ethanol solution containing LA and SA;

[0043] The core layer solution is prepared by: dissolving LMWF and ICG in a gelatin aqueous solution with a mass percentage concentration of 0.5% to form a mixed solution, wherein the LMWF concentration in the mixed solution is 4.5 mg / mL and the ICG concentration is 1 mg / mL;

[0044] (3) Preparation of the outer layer of the patch: accurately weigh 0.05 g of PCL using an electronic balance and dissolve it in 1 mL of hexafluoroisopropanol, stir it with a magnetic stirrer overnight until it is evenly mixed to obtain a PCL spinning solution with a mass concentration of 0.05 g / mL; fix the PCL / ADM random nanofiber membrane with deposited drug-loaded particles obtained in step (2) on a receiving plate, and use existing electrospinning equipment to prepare the PCL random nanofiber membrane. The spinning parameters are: the spinning solution flow rate is 1 mL / h, the distance between the nozzle and the receiving plate is 15 cm, the nozzle voltage is 15 kV, and the receiving plate voltage is -3 kV. After 1 hour, the PCL random nanofiber membrane is covered on the PCL / ADM random nanofiber membrane with deposited drug-loaded particles, thereby completing the preparation of an oral patch for controlled on-demand drug release.

[0045] In this example, the oral patch was characterized by SEM. The results are as follows Figure 1 As shown in A. Figure 1 A The results show that the oral patch is a sandwich-like multi-layer structure, and the drug-loaded particles deposited on the membrane can be clearly observed.

[0046] In this embodiment, a digital camera was used to photograph the prepared oral patch at different angles (front, back and side). The results are as follows: Figure 1B, 1C and 1D. The results showed that the front and back sides of the prepared oral patch were relatively smooth, without obvious droplets and particles, and no obvious stratification was observed from the side, indicating that the layers were tightly attached to each other.

[0047] Embodiment 2:

[0048] This embodiment relates to a method for preparing an oral patch for controlling the on-demand release of a drug, and the specific steps include:

[0049] (1) Preparation of the inner layer of the patch: 0.1 g of PCL and 0.05 g of ADM were accurately weighed with an electronic balance and dissolved in 3 mL of hexafluoroisopropanol, and stirred overnight with a magnetic stirrer to obtain a PCL / ADM spinning solution with a total mass concentration of 0.05 g / mL; the PCL / ADM random nanofiber membrane was prepared using an existing electrospinning device, and the spinning parameters were as follows: the spinning solution flow rate was 3 mL / h, the distance between the nozzle and the receiving plate was 12 cm, the nozzle voltage was 20 kV, and the receiving plate voltage was -3 kV. After 1 hour, the PCL / ADM random nanofiber membrane was obtained;

[0050] (2) Deposition of drug-loaded particles: The PCL / ADM random nanofiber membrane obtained in step (1) was fixed on a receiving plate, the receiving plate was connected to negative pressure, the distance between the receiving plate and the nozzle of the coaxial electrostatic spray device was 12 cm, the coaxial electrostatic spray device sprayed the drug-loaded particles to the surface of the nanofiber membrane, and the carrier particles were deposited on the surface of the nanofiber membrane for 10 min; the carrier particles were prepared by coaxial electrostatic spraying of a shell solution and a core solution, wherein the shell solution was a dichloromethane / anhydrous ethanol solution containing LA and SA, and the core solution was a gelatin aqueous solution containing rhodamine B and ICG, and rhodamine B was used as a model molecule to verify that the drug could be encapsulated inside the particles as a conceptual verification; the parameters of the coaxial electrostatic spray device were set as follows: the shell solution flow rate was 1 mL / h, the core solution flow rate was 0.1 mL / h, and the nozzle voltage was 15 kV;

[0051] The shell solution preparation method is as follows: accurately weigh 0.6 g of LA and 0.2 g of SA using an electronic balance and dissolve them in 5 mL of a dichloromethane / anhydrous ethanol mixed solvent, wherein the volume ratio of dichloromethane to anhydrous ethanol in the mixed solvent is 4:1, and stir with a magnetic stirrer for 5 hours until the mixture is uniformly stirred to obtain a dichloromethane / anhydrous ethanol solution containing LA and SA;

[0052] The core layer solution is prepared by: dissolving LMWF and ICG in a gelatin aqueous solution with a mass percentage concentration of 0.5% to form a mixed solution, wherein the LMWF concentration in the mixed solution is 4.5 mg / mL and the ICG concentration is 1 mg / mL;

[0053] (3) Preparation of the outer layer of the patch: accurately weigh 0.3 g of PCL using an electronic balance and dissolve it in 3 mL of hexafluoroisopropanol, stir it with a magnetic stirrer overnight until it is evenly mixed to obtain a PCL spinning solution with a mass concentration of 0.1 g / mL; fix the PCL / ADM random nanofiber membrane deposited with drug-loaded particles obtained in step (2) on a receiving plate, and use existing electrospinning equipment to prepare the PCL random nanofiber membrane. The spinning parameters are: the spinning solution flow rate is 3 mL / h, the distance between the nozzle and the receiving plate is 12 cm, the nozzle voltage is 20 kV, and the receiving plate voltage is -3 kV. After 1 hour, the PCL random nanofiber membrane is covered on the PCL / ADM random nanofiber membrane deposited with drug-loaded particles, thereby completing the preparation of an oral patch for controlling the on-demand release of drugs.

[0054] In this example, the drug-loaded microparticles were optically characterized using a fluorescence microscope. Figure 2 As shown in A: Each particle can be observed to fluoresce under fluorescence excitation, so the coaxial electrostatic spray method can be used to successfully prepare drug-loaded particles.

[0055] In this example, each layer of the three-layer nanopatch was characterized by SEM. The results are as follows: Figure 2 B, 2C and 2D. The results show that: Figure 2 As can be seen in B, the microparticles were successfully prepared. Figure 2 C and Figure 2 D are the inner and outer electrospun nanofibers, respectively.

[0056] Embodiment 3:

[0057] This example is an infrared response release experiment of the oral patch for controlling the on-demand release of drugs prepared in Example 1. The oral patch collected on the glass slide was placed at the bottom of a 24-well plate containing 500 μL of phosphate buffered saline (PBS), and the polysaccharide quantitative kit (DMMB method) measured the optical density (OD value) after each infrared stimulation, and calculated the cumulative release amount. The specific method is:

[0058] (1) Place the oral patches collected on the glass slide at the bottom of a 24-well plate containing 500 μL PBS;

[0059] (2) The laser irradiation parameters are as follows: the wavelength of the near-infrared laser is 808 nm, the intensity of the laser irradiation is 2200 mW, the laser irradiation time is 60 s, the laser irradiation distance is 2-3 cm, and after the temperature of the irradiated part reaches 39 °C as observed by the thermal imager, 100 μL of the solution is taken out and an equal amount of fresh PBS solution is added. During the measurement process, the 100 μL sample is mixed with 1.5 mL of 1,9-dimethylmethylene blue zinc chloride complex salt (DMMB) solution and added to a 96-well plate at a volume of 100 μL / well, and the absorbance is detected at 525 nm;

[0060] (3) after each infrared irradiation, repeat the method in step (2) and measure the OD value by the DMMB method;

[0061] (4) calculating the polysaccharide concentration of the sample to be tested at each time point according to the standard curve equation, and calculating the cumulative release amount and variance of the sample at each time point;

[0062] (5) The cumulative release amount and variance of the samples at each time point were plotted as a sustained-release curve; the oral patch was not subjected to infrared irradiation as a parallel control test. The results were as follows: Figure 3 shown.

[0063] from Figure 3 It can be seen that the cumulative release amount of the oral patch subjected to infrared irradiation shows an upward trend with the increase in the number of irradiations.

[0064] The preparation method of the DMMB solution is as follows: dissolving 4 mg of DMMB dye in 250 mL of ultrapure water; then, adding 0.75 g of glycine and 400 mg of sodium chloride to the obtained solution; adjusting the pH value to 3 with 1 mol / L hydrochloric acid, removing impurities from the DMMB solution with a 0.22 μm sterile filter membrane, and storing it in a dry and dark environment.

[0065] Embodiment 4:

[0066] This example is an experiment on the effect of the oral patch for controlled drug release on demand prepared in Example 1 on the proliferation of oral epithelial cells. Oral epithelial cells were seeded at a density of 10,000 cells / well in a 24-well plate containing the multilayer nanopatch prepared in Example 1, and infrared irradiation was performed. Cell proliferation was detected using a cell activity detection kit (CCK-8) on the 1st, 3rd, 5th, and 7th days of culture. The specific method includes the following steps:

[0067] (1) Oral epithelial cells were seeded at a density of 10,000 cells / well in a 24-well plate containing the multilayer nanopatch prepared in Example 1. After culturing for 1 day in a complete cell culture medium (volume percentage composition: 89% low-glucose Solarbio medium (DMEM) + 10% fetal bovine serum + 1% penicillin / streptomycin), the material was irradiated with infrared at an intensity of 2600 mW for 1 min, the old culture medium was removed, and then the material was washed 3 times with PBS;

[0068] (2) Prepare complete cell culture medium containing 10% CCK-8, add 500 μL to each well, and incubate at 37°C in the dark for 3 h;

[0069] (3) Transfer 100 μL of the liquid from each well to a 96-well plate and measure the OD value at 450 nm;

[0070] (4) Wash the 24-well plate three times with PBS, add complete cell culture medium again, and continue to culture in the cell culture incubator;

[0071] (5) After 3, 5, and 7 days of culture, the above method was repeated to detect cell activity (PCM-ICG-LMWF(+) group);

[0072] (6) Six parallel control experiments were designed (the parameters of the infrared irradiation experimental group involved were 2600 mW irradiation of the material for 1 min), namely, Control (-) group (cells seeded in a well plate and not treated with infrared irradiation), Free LMWF group (no co-incubation with materials, directly adding an equal amount of LMWF), PCM (-) group (no loading of drugs and photothermal agents and no infrared irradiation), PCM-ICG (-) group (only loaded with photothermal agents but no drugs and no infrared irradiation), PCM-ICG (+) group (only loaded with photothermal agents but no drugs and with infrared irradiation), PCM-ICG-LMWF (-) group (loaded with photothermal agents and drugs but no infrared irradiation). The results are shown in the figure. Figure 4 shown.

[0073] from Figure 4 It can be seen that compared with the 6 control groups, the oral epithelial cells grown on the oral patch of the present invention (PCM-ICG-LMWF(+)) showed good proliferation ability.

[0074] Embodiment 5:

[0075] This example is an experiment on the effect of the oral patch for controlled drug release on demand prepared in Example 1 on the morphology of oral epithelial cells. Oral epithelial cells were seeded at a density of 10,000 cells / well in a 24-well plate containing the oral patch prepared in Example 1. After 7 days of culture, infrared irradiation and fibrous actin green fluorescent dye (F-actin) / phenylindole (DAPI) staining were used to observe the cell morphology. The specific method includes the following steps:

[0076] (1) Oral epithelial cells were seeded at a density of 10,000 cells / well in a 24-well plate containing the oral patch prepared in Example 1, and cultured in a complete cell culture medium (89% DMEM + 10% fetal bovine serum + 1% penicillin / streptomycin by volume) for 7 days. The material was irradiated with infrared at an intensity of 2,600 mW for 1 min, the old culture medium was removed, and then washed with PBS three times;

[0077] (2) Fix the cells with 0.5 mL / well of 4% tissue cell fixative at room temperature for 30 min, remove the tissue cell fixative, and then wash three times with PBS;

[0078] (3) Permeabilize with 0.2 mL / well of 0.1% triton X-100 aqueous solution at room temperature for 5 min, remove the triton X-100 solution, and then wash with PBS three times;

[0079] (4) Block with 0.5 mL / well of 1% bovine serum albumin (BSA) aqueous solution for 30-60 min, remove the BSA solution and wash with PBS three times;

[0080] (5) F-actin and 1% BSA aqueous solution were mixed at a volume ratio of 1:1000, and then 200 μL of the mixture was added to each well and stained at room temperature in the dark for 45 min;

[0081] (6) Wash with PBS three times, 5 min each time;

[0082] (7) Seal the slides with a sealing medium containing DAPI, and observe and photograph them under a laser scanning confocal microscope (PCM-ICG-LMWF(+));

[0083] (8) Seven groups of parallel control experiments were designed (the parameters of the infrared irradiation experimental group involved were 2600 mW irradiation of the material for 1 min), namely, Control (-) group (cells seeded in the well plate and not treated with infrared irradiation), Control (+) group (cells seeded in the well plate and treated with infrared irradiation), Free LMWF group (no co-incubation with materials, directly adding the same amount of LMWF), PCM (-) group (no loading of drugs and photothermal agents and no infrared irradiation), PCM-ICG (-) group (only loaded with photothermal agents but no drugs and no infrared irradiation), PCM-ICG (+) group (only loaded with photothermal agents but no drugs and with infrared irradiation), PCM-ICG-LMWF (-) group (loaded with photothermal agents and drugs but no infrared irradiation). The results are as follows: Figure 5 shown.

[0084] from Figure 5 It can be seen that compared with the 7 control groups, the cells grown on the oral patch of the present invention (PCM-ICG-LMWF(+)) adhered and grew on the oral patch, and the cell morphology was good, indicating that the oral patch of the present invention can promote cell growth.

[0085] Embodiment 6:

[0086] This example is an experiment on the effect of the oral patch prepared in Example 1 on the morphology of oral squamous cell carcinoma cells. Oral squamous cell carcinoma cells were seeded at a density of 10,000 cells / well in a 24-well plate containing the multilayer patch prepared in Example 1. After culturing for 1 day, infrared irradiation and F-actin / DAPI staining were used to observe the cell morphology. The specific method includes the following steps:

[0087] (1) Oral squamous cell carcinoma cells were seeded at a density of 10,000 cells / well in a 24-well plate containing the oral patch prepared in Example 1, and cultured in complete cell culture medium (89% DMEM + 10% fetal bovine serum + 1% penicillin / streptomycin by volume) for 1 day, then irradiated with infrared at an intensity of 2600 mW for 1 min, the old culture medium was removed, and then washed with PBS 3 times;

[0088] (2) Fix the cells with 0.5 mL / well of 4% tissue cell fixative at room temperature for 30 min, remove the tissue cell fixative, and then wash three times with PBS;

[0089] (3) Permeabilize with 0.2 mL / well of 0.1% Triton X-100 aqueous solution at room temperature for 5 min, remove the Triton X-100 solution, and then wash with PBS three times;

[0090] (4) Block with 0.5 mL / well of 1% BSA aqueous solution for 30 min-60 min, remove the BSA solution and wash with PBS three times;

[0091] (5) F-actin and 1% BSA aqueous solution were mixed at a volume ratio of 1:1000, and then 200 μL of the mixture was added to each well and stained at room temperature in the dark for 45 min;

[0092] (6) Wash with PBS three times, 5 min each time;

[0093] (7) The sections were sealed with a sealing medium containing DAPI, and then observed and photographed under a laser scanning confocal microscope (PCM-ICG-LMWF(+) group);

[0094] (8) Seven parallel control groups were designed, including the Control(-) group (cells seeded in well plates without infrared irradiation), the Control(+) group (cells seeded in well plates with infrared irradiation), the Free LMWF group (without co-incubation with materials, and directly adding equal amounts of LMWF), the PCM(-) group (without loading of drugs and photothermal agents and without infrared irradiation), the PCM-ICG(-) group (with only loading of photothermal agents but no drugs and without infrared irradiation), the PCM-ICG(+) group (with only loading of photothermal agents but no drugs and with infrared irradiation), and the PCM-ICG-LMWF(-) group (with loading of photothermal agents and drugs but without infrared irradiation). The results are shown in Table 1. Figure 6 shown.

[0095] from Figure 6 It can be seen that compared with the 7 control groups, the oral squamous cell carcinoma cells grown on the oral patch of the present invention (PCM-ICG-LMWF(+)) no longer have cell morphology, indicating that the multilayer nanopatch can clear oral squamous cell carcinoma cells.

[0096] Embodiment 7:

[0097] This example is the effect of the multilayer nanopatch prepared in Example 1 on the apoptosis of oral squamous cell carcinoma cells. Oral squamous cell carcinoma cells were seeded at a density of 30,000 cells / well in a 24-well plate containing the multilayer patch prepared in Example 1. After culturing for 1 day, infrared stimulation was performed and cell apoptosis was detected by flow cytometry. The specific method includes the following steps:

[0098] (1) Oral squamous cell carcinoma cells were seeded at a density of 30,000 cells / well in a 24-well plate containing the oral patch prepared in Example 1, and cultured in complete cell culture medium (89% DMEM + 10% fetal bovine serum + 1% penicillin / streptomycin by volume) for 1 day. The material was then irradiated with infrared light at an intensity of 2600 mW for 1 min, the old culture medium was removed, and then the material was washed 3 times with PBS;

[0099] (2) Add 500 μL of trypsin to each well and place in a cell culture incubator for 6 min;

[0100] (3) Add 500 μL of complete cell culture medium to each well to terminate digestion, centrifuge at 900 rpm for 5 min, discard the supernatant, wash the cells once with PBS, discard the supernatant after centrifugation, and add 100 μL of 1× Annexin V Binding Buffer working solution to resuspend the cells;

[0101] (4) Add 2.5 μL of Annexin V-APC and 2.5 μL of propidium iodide (PI) staining solution to the cell suspension;

[0102] (5) After gently vortexing, incubate at room temperature in the dark for 15-20 min, add 400 μL of diluted 1× Annexin V Binding Buffer working solution, and mix the sample;

[0103] (6) On-machine testing (PCM-ICG-LMWF(+) group);

[0104] (7) Seven parallel control experiments were designed, including Control(-) group (cells seeded in well plates without infrared irradiation), Control(+) group (cells seeded in well plates with infrared irradiation), Free LMWF group (without co-incubation with materials, and directly adding equal amounts of LMWF), PCM(-) group (without loading of drugs and photothermal agents and without infrared irradiation), PCM-ICG(-) group (with only loading of photothermal agents but no drugs and without infrared irradiation), PCM-ICG(+) group (with only loading of photothermal agents but no drugs and with infrared irradiation), and PCM-ICG-LMWF(-) group (with loading of photothermal agents and drugs but without infrared irradiation). The experimental results are shown in the table below. Figure 7 shown.

[0105] from Figure 7 It can be seen that compared with the 7 control groups, the oral patch grown on the oral patch of the present invention (PCM-ICG-LMWF(+)) combined with infrared stimulation has a significant clearing effect on cancer cells.

Claims

1. An oral patch for controlling the on-demand release of a drug, characterized in that: The main structure includes an inner layer of the patch, drug-carrying particles and an outer layer of the patch. The inner layer of the patch is a uniaxial random or centripetally oriented medical degradable polymer nanofiber membrane; the drug-carrying particles are located between the inner layer of the patch and the outer layer of the patch and deposited on the inner layer of the patch; the outer layer of the patch is a random nanofiber of medical degradable polymer, covering the surface of the inner layer of the patch where the drug-carrying particles are deposited; the inner layer of the patch contains bioactive substances; the bioactive substances are acellular dermal matrix; the addition of bioactive substances effectively promotes the proliferation of oral epithelial cells and promotes the regeneration of oral epithelium in damaged areas; The medical degradable polymer is at least one of polylactic acid, polycaprolactone, polylactic acid-glycolic acid copolymer, and polylactic acid-caprolactone copolymer; The drug-loaded particles include a core layer and a shell layer, the core layer is a mixture of a drug and a photothermal initiator, and the shell layer is a mixture containing a phase change material; The drug is low molecular weight brown algae polysaccharide; the photothermal initiator is at least one of indocyanine green and heptamethine cyanine small molecule dyes; the phase change material is lauric acid and stearic acid, and the mass ratio of the two is at least one of 4:1, 3:1, 2:1, and 1:

1.

2. The method for preparing the oral patch for controlling the on-demand release of drugs according to claim 1, characterized in that: The specific steps include: (1) Preparing the inner layer of the patch: the medical degradable polymer and the bioactive substance are mixed and dissolved evenly in an organic solvent to obtain a spinning solution, and then a uniaxial random or centripetally oriented polymer nanofiber membrane is prepared by a single-nozzle electrospinning device, which is the inner layer of the patch; (2) Deposition of drug-loaded particles: The drug-loaded particles are prepared by spraying the shell layer solution and the core layer solution through a coaxial electrostatic spray device, and the sprayed drug-loaded particles are deposited on the inner surface of the patch obtained in step (1); (3) Preparing the outer layer of the patch: dissolving the medical degradable polymer in an organic solvent, and then using existing electrospinning equipment to prepare a random nanofiber membrane, which is covered on the inner layer surface of the patch where the drug-loaded particles are deposited, to obtain a three-layer structured oral patch for controlled on-demand drug release; In step (1), the mass ratio of the medical degradable polymer to the bioactive substance is 1: (0.5-1), and the volume ratio of the total mass of the medical degradable polymer and the bioactive substance to the organic solvent is (1-5) g: 10 mL; in step (3), the volume ratio of the mass of the medical degradable polymer to the organic solvent is (5-10) g: 10 mL; The preparation parameters of the drug-loaded microparticles in step (2) are: the flow rate of the shell solution is 1-5 mL / h, the flow rate of the core solution is 0.1-1.0 mL / h, the nozzle voltage is 15-20 kV, the receiving plate is grounded, and the distance between the nozzle and the plate is 12-15 cm.